Keywords: Biotechnology, GSK, Vernalis
Vernalis in deal with GSK worth a potential $200 million or more
Article | 07 August 2009
Loss-making UK-based biotechnology firm Vernalis has entered into an exclusive collaboration, option and license agreement with drug giant GlaxoSmithKline relating ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
